{"id":8271,"date":"2021-03-15T15:36:41","date_gmt":"2021-03-15T15:36:41","guid":{"rendered":"https:\/\/thepublicationplan.com\/?p=8271"},"modified":"2021-03-15T15:36:41","modified_gmt":"2021-03-15T15:36:41","slug":"improving-access-to-scientific-research-open-pharma-resource-available","status":"publish","type":"post","link":"https:\/\/thepublicationplan.com\/2021\/03\/15\/improving-access-to-scientific-research-open-pharma-resource-available\/","title":{"rendered":"Improving access to scientific research: Open Pharma resource available"},"content":{"rendered":"
<\/div>\n

\"\"<\/a><\/p>\n

Open access publishing has been gaining momentum over recent years. A survey<\/a> by the Wiley Network<\/a> last year concluded that open data is \u201chere to stay\u201d, with over half of respondents believing that \u201copen data is more important now than it was 12 months ago\u201d.<\/p>\n

The Open Pharma<\/a> collaboration between healthcare stakeholders launched a position statement<\/a> in 2019, advocating for open access (OA) publishing of pharma-based research to improve transparency, advance scientific knowledge and improve patient care. One year on, during Open Access Week 2020<\/a>, they released a set of educational slides \u2018Open access. The new standard for pharma publications<\/em><\/a>\u2019 to help further their objectives.<\/p>\n

The presentation provides an overview of what OA means for pharma, healthcare stakeholders and patients, highlighting features such as accessibility, equity, trust, scientific exchange and improved patient care. The authors note that paywalls may prevent research from being accessed by key groups, including patients and their families, patient advocates, policymakers, academic researchers, healthcare professionals, and journalists or other communications professionals. In addition to ensuring that research is made available to those who need it, other benefits of OA encompass increased citations, social media activity and downloads by healthcare professionals.<\/p>\n

The group suggests several steps that pharma can take to drive change towards increased OA using the acronym BECAUSE:<\/p>\n